OliX PharmaceuticalsInc (226950) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.023x

Based on the latest financial reports, OliX PharmaceuticalsInc (226950) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.23 Billion ≈ $2.19 Million USD) by net assets (₩142.56 Billion ≈ $96.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

OliX PharmaceuticalsInc - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how OliX PharmaceuticalsInc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OliX PharmaceuticalsInc (226950) total liabilities for a breakdown of total debt and financial obligations.

OliX PharmaceuticalsInc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of OliX PharmaceuticalsInc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ningbo Boway Alloy Material Co Ltd SHG:601137	-0.062x
Immunome Inc NASDAQ:IMNM	-0.076x
Terna Energy Societe Anonyme Commercial Technical Company AT:TENERGY	0.071x
Ardagh Metal Packaging SA NYSE:AMBP	-0.542x
Washington Federal Inc NASDAQ:WAFD	0.020x
Easyhome New Retail Group Co Ltd SHE:000785	0.036x
Krungthai Card PCL BK:KTC	0.058x
Zhejiang Shenghua Biok Biology Co Ltd SHG:600226	0.021x

Annual Cash Flow Conversion Efficiency for OliX PharmaceuticalsInc (2016–2024)

The table below shows the annual cash flow conversion efficiency of OliX PharmaceuticalsInc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of OliX PharmaceuticalsInc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩17.85 Billion ≈ $12.10 Million	₩-28.04 Billion ≈ $-19.01 Million	-1.571x	-273.62%
2023-12-31	₩50.34 Billion ≈ $34.11 Million	₩-21.17 Billion ≈ $-14.35 Million	-0.421x	+9.67%
2022-12-31	₩65.91 Billion ≈ $44.66 Million	₩-30.68 Billion ≈ $-20.79 Million	-0.466x	+54.75%
2021-12-31	₩18.52 Billion ≈ $12.55 Million	₩-19.05 Billion ≈ $-12.91 Million	-1.029x	-1139.29%
2020-12-31	₩45.29 Billion ≈ $30.69 Million	₩-3.76 Billion ≈ $-2.55 Million	-0.083x	+67.67%
2019-12-31	₩41.80 Billion ≈ $28.33 Million	₩-10.73 Billion ≈ $-7.27 Million	-0.257x	-68.76%
2018-12-31	₩54.94 Billion ≈ $37.23 Million	₩-8.36 Billion ≈ $-5.67 Million	-0.152x	+40.64%
2017-12-31	₩18.68 Billion ≈ $12.66 Million	₩-4.79 Billion ≈ $-3.24 Million	-0.256x	+6.67%
2016-12-31	₩12.56 Billion ≈ $8.51 Million	₩-3.45 Billion ≈ $-2.34 Million	-0.275x	--

About OliX PharmaceuticalsInc

KQ:226950 Korea Biotechnology

Market Cap

$2.35 Billion

₩3.47 Trillion KRW

Market Cap Rank

#5669 Global

#145 in Korea

Share Price

₩172500.00

Change (1 day)

-6.55%

52-Week Range

₩34800.00 - ₩207000.00

All Time High

₩207000.00